Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 268

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 1B
Chunk 268
---
 in accordance with GAAP. Our internal
control over financial reporting includes those policies and procedures that:

(1)pertain
to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets
of our company,

(2)provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP,
and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors, and

(3)provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could
have a material effect on the financial statements.

Because
of its inherent limitations, internal control over financial reporting may not prevent or detect errors or misstatements in our financial
statements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate. Management, including
our Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting
at December 31, 2024. In making these assessments, management used the criteria set forth by the Committee of Sponsoring Organizations
of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). Based on our assessments and those criteria, management
determined that we maintained effective internal control over financial reporting as of December 31, 2024.

This
Report on does not include an attestation report of internal controls from our independent registered public accounting firm due to our
status as an emerging growth company under the JOBS Act.

Changes
in Internal Control over Financial Reporting

During
the quarter ended December 31, 2024, there has been no change in our internal control over financial reporting that has materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.

Item
9B. Other Information.

Not
applicable.

Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not
applicable.

23

PART
III

Item
10. Directors, Executive Officers and Corporate Governance.

Directors
and Executive Officers

Our
directors and executive officers are as follows:

    Name
     
    Age
     
    Title
  
    Lei
    Huang
     
    53
     
    Chief
    Executive Officer and Director
  
    You
    (“